The estimated Net Worth of Advisors Llc Orbi Med Capit... is at least $328 Milione dollars as of 11 May 2023. Advisors Capit owns over 482,913 units of Graybug Vision stock worth over $20,777,779 and over the last 7 years Advisors sold GRAY stock worth over $306,996,474.
Advisors has made over 30 trades of the Graybug Vision stock since 2018, according to the Form 4 filled with the SEC. Most recently Advisors sold 482,913 units of GRAY stock worth $9,938,350 on 11 May 2023.
The largest trade Advisors's ever made was selling 6,139,864 units of Graybug Vision stock on 22 December 2022 worth over $135,997,988. On average, Advisors trades about 483,466 units every 59 days since 2018. As of 11 May 2023 Advisors still owns at least 3,777,778 units of Graybug Vision stock.
You can see the complete history of Advisors Capit stock trades at the bottom of the page.
Advisors's mailing address filed with the SEC is 601 Lexington Ave, New York, NY 10022, USA.
Over the last 4 years, insiders at Graybug Vision have traded over $0 worth of Graybug Vision stock and bought 2,393,750 units worth $38,300,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., James E Deerfield Mgmt Hif,... e Frederic Guerard. On average, Graybug Vision executives and independent directors trade stock every 35 days with the average trade being worth of $720,841. The most recent stock trade was executed by Robert S Breuil on 14 March 2023, trading 5,000 units of GRAY stock currently worth $27,500.
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Graybug Vision executives and other stock owners filed with the SEC include: